Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02108392
Other study ID # pending
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 2014
Est. completion date December 2018

Study information

Verified date June 2018
Source University Hospital, Bonn
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Pseudoxanthoma elasticum (PXE) is a rare multisystem disorder of autosomal recessive inheritance (OMIM# 264800) and an estimated prevalence between 1:25.000 and 1:100.000. PXE is characterized by calcification and fragmentation of connective tissue rich in elastic fibers. Due to its high content of elastic fibers, Bruch Membrane in eyes of patients affected by PXE becomes thickened and calcified. The ocular phenotype is characterized by angioid streaks and peau d'orange but also choroidal neovascularizations and chorioretinal atrophy thereby in part mimicking the phenotype of age-related macular degeneration. The disease is due to mutations of the ABCC6-gene coding for a transmembrane protein which is mainly expressed in the liver and kidney. It is hypothesized that ABCC6 is involved in the excretion of a yet unknown factor from the liver which inhibits systemic calcification. In animal models several candidates for this factor have been identified but direct evidence for such a factor in patients with PXE is still missing. The primary purpose of this study is to further investigate the ocular phenotype of patients with PXE using multimodal imaging and functional testing to delineate the impact of Bruch membrane pathology on the eye. Furthermore, possible systemic anti-calcification factors, as well as associations with the vascular alterations are investigated to gain more insights into the pathogenesis of PXE..


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Diagnosis of Pseudoxanthoma elastcium based on histopathologic and/or genetic testing

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Department of Ophthalmology, University of Bonn Bonn NRW

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bonn

Country where clinical trial is conducted

Germany, 

References & Publications (11)

Charbel Issa P, Finger RP, Götting C, Hendig D, Holz FG, Scholl HP. Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology. 2010 Jul;117(7):1406-14. doi: 10.1016/j.ophtha.2009.11.008. Epub 2010 Mar 1. — View Citation

Charbel Issa P, Finger RP, Holz FG, Scholl HP. Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterization of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5913-8. doi: 10.1167/iovs.09-3541. Epub 2009 Jun 24. — View Citation

Charbel Issa P, Gliem M, Holz FG, Knabbe C, Hendig D. [Pseudodominant inheritance of pseudoxanthoma elasticum]. Ophthalmologe. 2015 Aug;112(8):686-90. doi: 10.1007/s00347-014-3231-9. Review. German. — View Citation

Finger RP, Charbel Issa P, Ladewig M, Götting C, Holz FG, Scholl HP. Fundus autofluorescence in Pseudoxanthoma elasticum. Retina. 2009 Nov-Dec;29(10):1496-505. doi: 10.1097/IAE.0b013e3181aade47. — View Citation

Finger RP, Fenwick E, Marella M, Charbel Issa P, Scholl HP, Holz FG, Lamoureux EL. The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum. Health Qual Life Outcomes. 2011 Dec 12;9:113. doi: 10.1186/1477-7525-9-113. — View Citation

Gliem M, Fimmers R, Müller PL, Brinkmann CK, Finger RP, Hendig D, Holz FG, Charbel Issa P. Choroidal changes associated with Bruch membrane pathology in pseudoxanthoma elasticum. Am J Ophthalmol. 2014 Jul;158(1):198-207.e3. doi: 10.1016/j.ajo.2014.04.005. Epub 2014 Apr 13. — View Citation

Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P. Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina. 2013 Jul-Aug;33(7):1300-14. doi: 10.1097/IAE.0b013e3182914d2b. Review. — View Citation

Gliem M, Hendig D, Finger RP, Holz FG, Charbel Issa P. Reticular pseudodrusen associated with a diseased bruch membrane in pseudoxanthoma elasticum. JAMA Ophthalmol. 2015 May;133(5):581-8. doi: 10.1001/jamaophthalmol.2015.117. Erratum in: JAMA Ophthalmol. 2015 May;133(5):621. — View Citation

Gliem M, Müller PL, Birtel J, Hendig D, Holz FG, Charbel Issa P. Frequency, Phenotypic Characteristics and Progression of Atrophy Associated With a Diseased Bruch's Membrane in Pseudoxanthoma Elasticum. Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3323-30. doi: 10.1167/iovs.16-19388. — View Citation

Gliem M, Müller PL, Birtel J, McGuinness MB, Finger RP, Herrmann P, Hendig D, Holz FG, Charbel Issa P. Quantitative Fundus Autofluorescence in Pseudoxanthoma Elasticum. Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6159-6165. doi: 10.1167/iovs.17-22007. — View Citation

Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P. An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet. 2013 Apr 4;4:14. doi: 10.3389/fgene.2013.00014. eCollection 2013. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Ocular phenotype Patients are investigated using a multimodal imaging approach and visual function testing. patients will be followed longitudinally with an expected 1-year average interval between visits
Secondary Biomarkers in PXE Potential systemic biomarkers are investigated by collecting blood samples of PXE patients 1 day (first visit)
See also
  Status Clinical Trial Phase
Completed NCT02537054 - Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE) Phase 2
Active, not recruiting NCT05569252 - A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum Phase 2
Recruiting NCT05662085 - Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
Completed NCT03070860 - What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum N/A
Completed NCT01446393 - Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE) N/A
Completed NCT00470977 - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Phase 1/Phase 2
Recruiting NCT03758534 - Natural History of GACI With or Without ARHR2 or PXE
Recruiting NCT01446380 - Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort N/A
Recruiting NCT03813550 - Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study) N/A
Not yet recruiting NCT03364504 - Biological Collection of Kidney Cells N/A
Recruiting NCT01731080 - Arterial Wall Calcium Load in Pseudoxanthoma Elasticum N/A
Completed NCT00555113 - Evolution of Visual Impairment During Pseudoxanthoma Elasticum N/A
Completed NCT00341419 - Genetic Analysis of Patients With Pseudoxanthoma Elasticum
Withdrawn NCT04441671 - Oral Pyrophosphate Absorption in PXE Disease Phase 2
Recruiting NCT04868578 - PPI Supplementation to Fight ECtopIc Calcification in PXE N/A
Completed NCT05025722 - Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
Completed NCT01525875 - Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE) Phase 2
Completed NCT05246189 - Employment of Patients With Pseudoxanthoma Elasticum
Recruiting NCT05832580 - The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum Phase 3
Active, not recruiting NCT05030831 - Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE Phase 1/Phase 2